Heart Failure Management Quiz

Which of the following is a primary goal of using neurohormonal antagonists in the management of early-stage heart failure (HF)?

• Facilitating ventricular recovery and preventing the development of clinical HF

• Reducing blood glucose levels

• Increasing heart rate

• Preventing pulmonary embolism

According to the text, which class of drugs is NOT mentioned as part of the evidence-based pharmacologic therapy for symptomatic chronic heart failure with reduced ejection fraction (HFrEF)?

• Calcium channel blockers

• Renin-angiotensin-aldosterone system (RAAS) antagonists

• β-adrenergic receptor antagonists

• Neprilysin inhibitors

What is a key difference in the management of patients with heart failure with preserved ejection fraction (HFpEF) compared to those with reduced ejection fraction (HFrEF)?

• There is a lack of evidence to support specific pharmacologic therapies to modify disease progression in HFpEF.

• HFpEF patients are always treated with device-based therapies.

• HFpEF management focuses solely on surgical intervention.

• HFpEF patients do not require any follow-up care.

Why might consideration of cardiac transplant or mechanical circulatory support be appropriate in patients with advanced or refractory heart failure (ACC/AHA stage D)?

• Because the risk of mortality from sudden death or end-stage HF is high

• Because these patients always respond well to medication

• Because these therapies are less expensive than pharmacologic therapy

• Because these patients do not require chronic ambulatory management

A patient with both HFrEF and HFpEF is at risk for clinical deterioration. What is a typical consequence that leads to this deterioration?

• Progressive sodium and fluid retention

• Increased bone density

• Improved cardiac output

• Reduced risk of hospitalization

Which of the following best describes the focus of management for acute decompensated heart failure (ADHF) exacerbations?

• Hemodynamic stabilization, decongestion, and institution of appropriate disease-modifying therapy

• Immediate surgical intervention for all patients

• Long-term use of antibiotics

• Discontinuation of all medications

Which of the following pharmacologic therapies has NOT conclusively demonstrated a mortality reduction in patients with Heart Failure with Preserved Ejection Fraction (HFpEF)?

• Angiotensin-converting enzyme inhibitors

• Angiotensin receptor blockers

• Neprilysin inhibitors

• All of the above

What is a common focus of management for patients with HFpEF according to the general principles discussed in the text?

• Aggressive surgical intervention

• Symptom improvement and prevention of disease progression through lifestyle modification and management of comorbidities

• Exclusive use of beta-blockers

• High-dose diuretic therapy only

Which clinical trial showed a statistically significant reduction in HF hospitalizations but no difference in all-cause mortality in patients with HFpEF?

• CHARM Preserved study

• PARADIGM-HF trial

• TOPCAT trial

• RELAX trial

According to the text, what is a novel target for understanding the pathophysiology of HFpEF?

• Myocardial infarction

• Microvascular endothelial inflammation

• Pulmonary embolism

• Aortic stenosis